Aurora kinase inhibitors for inhibiting mitotic progression

Patent metadata

Field	Value
Publication number	US-9988384-B2
Application number	US-201113217729-A
Country	US
Kind code	B2
Filing date	Aug 25, 2011
Priority date	Nov 16, 2006
Publication date	Jun 5, 2018
Grant date	Jun 5, 2018

Abstract

The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

First claim

What is claimed is:

1. A method for inhibiting Aurora kinase activity in a cell, comprising contacting a cell in which inhibition of Aurora kinase is desired with the compound

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the Aurora kinase is Aurora A kinase.

3. A method for treating cancer in a patient having cancer, comprising administering to the patient a therapeutically effective amount of the compound

or a pharmaceutically acceptable salt thereof, wherein
the cancer is colorectal cancer, ovarian cancer, breast cancer, gastric cancer, prostate cancer, pancreatic cancer, bladder cancer, renal cancer, hepatocellular cancer, lung cancer, cervical cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, brain tumor, bone cancer, soft tissue sarcoma, progressive epithelial or primary peritoneal cancer, acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or myelodysplastic syndromes.

4. The method of claim 3 , wherein the compound is sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate.

5. A method for treating cancer in a patient having cancer, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising the compound

or a pharmaceutically acceptable salt thereof, wherein
the cancer is colorectal cancer, ovarian cancer, breast cancer, gastric cancer, prostate cancer, pancreatic cancer, bladder cancer, renal cancer, hepatocellular cancer, lung cancer, cervical cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancer, brain tumor, bone cancer, soft tissue sarcoma, progressive epithelial or primary peritoneal cancer, acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, or myelodysplastic syndromes.

6. The method of claim 3 , wherein the cancer is ovarian cancer.

7. The method of claim 3 , wherein the cancer is T-cell lymphoma.

8. The method of claim 5 , wherein the cancer is ovarian cancer.

9. The method of claim 5 , wherein the cancer is T-cell lymphoma.

10. The method of claim 3 , wherein the cancer is metastatic breast cancer.

11. The method of claim 3 , wherein the cancer is androgen-dependent or androgen-independent prostate cancer.

12. The method of claim 3 , wherein the cancer is metastatic renal cell carcinoma.

13. The method of claim 3 , wherein the cancer is non-small cell lung cancer.

14. The method of claim 3 , wherein the cancer is bronchioloalveolar carcinoma or adenocarcinoma of the lung.

15. The method of claim 3 , wherein the cancer is squamous cell carcinoma of the head and neck.

16. The method of claim 3 , wherein the cancer is metastatic neuroendocrine tumor.

17. The method of claim 3 , wherein the cancer is glioma.

18. The method of claim 3 , wherein the cancer is anaplastic oligodendroglioma, adult glioblastoma multiforme or adult anaplastic astrocytoma.

19. The method of claim 3 , wherein the cancer is follicular lymphoma, mantle cell lymphoma, B-cell lymphoma, T-cell lymphoma or Waldenstrom's macroglobulinemia.

Assignees

• Claiborne Christopher F
• Sells Todd B
• Stroud Stephen G
• Millennium Pharm Inc

Inventors

• Claiborne Christopher F
• Sells Todd B
• Stroud Stephen G

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• A61K31/55

  having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title